Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond-Reference-Cited by-同舟云学术

Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond

Published:2021-04-01 Issue:7 Volume:21 Page:811-824
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Perez Jose¹²,Garrigós Laia¹,Gion Maria³⁴,Jänne Pasi A.⁵,Shitara Kohei⁶,Siena Salvatore⁷⁸,Cortés Javier¹²⁹

Affiliation:

1. International Breast Cancer Center, Quiron Group, Barcelona, Spain

2. Medical Department, Medica Scientia Innovation Research (MedSIR), Valencia, Spain

3. Quironsalud Group, Madrid, Spain

4. Department of Medical Oncology, Hospital Universitario Ramón Y Cajal, Madrid, Spain

5. Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

6. Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan

7. Department of Oncology and Hematology-Oncology, Università Degli Studi Di Milano, Milan, Italy

8. Niguarda Cancer Center Grande Ospedale Metropolitano Niguarda, Milan, Italy

9. Department of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Funder

This paper is funded by Daiichi Sankyo.

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2021.1890710

Reference77 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines): breast cancer. (Version 6.2020). 2020 Sept 8. [cited November 18, 2020] Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

4. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy

5. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients;Cancer Biotherapy and Radiopharmaceuticals;2024-08-01

2. Trastuzumab deruxtecan in breast cancer;Critical Reviews in Oncology/Hematology;2024-06

3. Quantifying payloads of antibody‒drug conjugates using a postcolumn infused-internal standard strategy with LC‒MS;Analytica Chimica Acta;2024-05

4. The efficacy and safety of trastuzumab and albumin-bound paclitaxel with or without pyrotinib as neoadjuvant therapy for HER2-positive breast cancer: a prospective observational cohort study;Gland Surgery;2024-05

5. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial;The Lancet Oncology;2024-05